Targeting integrins in malignant glioma.

Details

Ressource 1Download: serval:BIB_91F72FFCA0A0.P001 (143.66 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_91F72FFCA0A0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Targeting integrins in malignant glioma.
Journal
Targeted Oncology
Author(s)
Tabatabai G., Weller M., Nabors B., Picard M., Reardon D., Mikkelsen T., Ruegg C., Stupp R.
ISSN
1776-260X (Electronic)
ISSN-L
1776-2596
Publication state
Published
Issued date
2010
Volume
5
Number
3
Pages
175-181
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The integrin family of cell adhesion receptors is emerging as a promising target of anticancer therapy. AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. Durable remissions have been observed in phase I and phase II trials for recurrent glioblastoma (GBM) with both lower and higher doses of cilengitide. Pilot trials in newly diagnosed glioblastoma in conjunction with standard chemoradiotherapy have been encouraging. Preclinical data suggest synergy with concomitant chemo- and radiation therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients is currently recruiting. This paper summarizes the current understanding of the role of integrins and their inhibition in gliomagenesis. The background and design of ongoing trials are outlined.
Keywords
Antineoplastic Agents/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/metabolism, Clinical Trials as Topic, Glioma/drug therapy, Glioma/metabolism, Humans, Integrins/antagonists & inhibitors, Signal Transduction
Pubmed
Web of science
Open Access
Yes
Create date
20/10/2010 16:19
Last modification date
01/10/2019 7:18
Usage data